Active, not recruitingNot applicableNCT04736121
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sirtex Medical
- Principal Investigator
- Armeen Mahvash, M.D., MDM.D. Anderson Cancer Center
- Intervention
- Resin microspheres containing yttrium-90 (Y-90)(device)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (22)
- University of California Los Angeles - Ronald Reagan Medical Center, Los Angeles, California, United States
- Providence St. Joseph Hospital, Orange, California, United States
- University of California Irvine, Orange, California, United States
- Miami Cardiac and Vascular Institute at Baptist Hospital, Miami, Florida, United States
- Sarasota Memorial Health Care System, Sarasota, Florida, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Columbia University CUIMC/NYPH, New York, New York, United States
- University of North Carolina - Chapel Hill Medical Center, Chapel Hill, North Carolina, United States
- Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
- University of Cincinnati Cancer Center CTO, Cincinnati, Ohio, United States
- The Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Hospital of the University Pennsylvania, Philadelphia, Pennsylvania, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
Bright Research Partners
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04736121 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital